Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Molecular Medicine Reports
Join Editorial Board Propose a Special Issue
Print ISSN: 1791-2997 Online ISSN: 1791-3004
Journal Cover
November-2017 Volume 16 Issue 5

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
November-2017 Volume 16 Issue 5

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article Open Access

Tanshinone IIA induces apoptosis via inhibition of Wnt/β‑catenin/MGMT signaling in AtT‑20 cells

  • Authors:
    • Zong‑Yang Li
    • Guo‑Dong Huang
    • Lei Chen
    • Ce Zhang
    • Bao‑Dong Chen
    • Qing‑Zhong Li
    • Xiang Wang
    • Xie‑Jun Zhang
    • Wei‑Ping Li
  • View Affiliations / Copyright

    Affiliations: Brain Center, Shenzhen Key Laboratory of Neurosurgery, Shenzhen Second People's Hospital, Shenzhen University 1st Affiliated Hospital, Shenzhen, Guangdong 518035, P.R. China
    Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
  • Pages: 5908-5914
    |
    Published online on: August 22, 2017
       https://doi.org/10.3892/mmr.2017.7325
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

A strategy to suppress the expression of the DNA repair enzyme O6‑methylguanine‑DNA methyltransferase (MGMT) by inhibition of Wnt/β‑catenin signaling may be useful as a novel treatment for pituitary adenoma. Previous studies have reported that Tanshinone IIA (TSA), a major quinone compound isolated from Salvia miltiorrhiza, had antitumor effects. However, whether TSA has antitumor effects against pituitary adenoma and whether the mechanisms are associated with the Wnt/β‑catenin/MGMT pathway remains to be clarified. In the present study, TSA treatment caused apoptosis in AtT‑20 cells in a concentration‑dependent manner, as demonstrated by cell viability reduction, phophatidylserine externalization detected by Annexin V staining and mitochondrial membrane potential disruption detected by JC‑1 staining, which were associated with activation of caspase‑3 and DNA fragmentation detected by TUNEL in AtT‑20 cells. T‑cell factor (TCF)‑lymphoid‑enhancing factor (LEF) reporter activity was determined by dual luciferase reporter assay and the interaction between β‑catenin and TCF‑4 were detected using a co‑immunoprecipitation kit. The results indicated TSA treatment increased β‑catenin phosphorylation, inhibited β‑catenin nuclear translocation, reduced β‑catenin/TCF‑4 complex formation and TCF‑LEF luciferase reporter activity, and subsequently reduced the expression of cyclin D1 and MGMT. Notably, overexpression of MGMT in β‑catenin knock down AtT‑20 cells abrogated the TSA‑mediated effects in AtT‑20 cells. In conclusion, TSA induced apoptosis via inhibition of Wnt/β‑catenin‑dependent MGMT expression, which may provide novel insights into the understanding of the mechanism of the antitumor effects of Salvia miltiorrhiza.

Introduction

Pituitary adenomas account for ~10% of intracranial tumors, and 5% are locally invasive (1). Although the etiology of pituitary adenoma is not fully understood, numerous experimental and clinical observations indicate that DNA repair enzyme O6-methylguanine-DNA methyltransferase (MGMT) is implicated in the pathogenesis of various tumor types, including pituitary adenoma (2,3). MGMT is a ubiquitous highly expressed enzyme that removes alkylating lesions at the O6 position of guanine to repair DNA damage (4).

MGMT is regulated by multiple molecular mechanisms, including epigenetic silencing of the MGMT gene by promoter methylation, histone modifications and aberrant expression of transcriptional activators and repressors, microRNAs and activation of the canonical Wnt/β-catenin signaling cascade (5). In the absence of Wnt ligands, cytoplasmic β-catenin is phosphorylated and degraded by the proteasome. However, a large pool of soluble non-phosphorylated β-catenin exists in the presence of Wnt ligands. β-catenin is then translocated to the nucleus where it interacts with T-cell factor (TCF)/lymphoid-enhancing factor (LEF) family transcription factors, such as TCF-4, to activate Wnt pathway target genes, including cyclin D1 and MGMT (6). In fact, growing evidence indicates that inhibition of Wnt/β-catenin signaling may have antitumor effects (7).

Tanshinone IIA (TSA) is the main quinone compounds isolated from Salvia miltiorrhiza, which have been used for various medicinal purposes in traditional Chinese medicine for many years. Experimental and clinical studies suggest that TSA has antitumor effects (8,9). Whether TSA has antitumor effects against pituitary adenomas, and whether the mechanisms are associated with Wnt/β-catenin/MGMT signaling remains to be clarified.

In the present study, AtT-20 mouse pituitary cells were used to evaluate the potential antitumor effect of TSA against pituitary adenoma and the underlying mechanism. Wnt/β-catenin/MGMT pathway inactivation was involved in antitumor effect of TSA against pituitary adenoma.

Materials and methods

Reagents

TSA (purity >98%), dimethyl sulfoxide (DMSO) and 4′,6-diamidino-2-phenylindole (DAPI) were purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS) and phosphate-buffered saline (PBS) were purchased from Gibco (Thermo Fisher Scientific, Inc., Waltham, MA, USA). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and 5,5′,6,6′-tetrachloro-1,1′, 3,3′-tetraethylbenzimidazolylcarbocyanine iodide (JC-1) were obtained from Enzo Life Sciences, Inc. (Farmingdale, NY, USA). Cell nuclear protein extraction kits, MGMT lentiviral activation particles and and control lentiviral activation particles, β-catenin short hairpin RNA (shRNA) lentiviral particle and control shRNA plasmid, Polybrene, and puromycin dihydrochloride were obtained from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA).

Cell culture and drug preparation

AtT-20 cells obtained from the Typical Culture Preservation Commission Cell Bank, Chinese Academy of Sciences (Shanghai, China) were cultured at 37°C in 5% CO2 and 95% atmosphere in DMEM medium supplemented with 5% FBS and glutamine (2 mM). To overexpress MGMT in β-catenin knock down cells, AtT-20 cells were cultured in 6-well plate (5×104 cells/ml) and cultured to 60% confluency. Cells were transfected with MGMT lentiviral activation particles (1×105/ml) and β-catenin shRNA lentiviral particle (1×105/ml) in complete medium with Polybrene (5 µg/ml) and incubated overnight. Stable clones were selected using puromycin dihydrochloride (5 µg/ml). The mRNA and protein expression of β-catenin or MGMT were determined by reverse transcription-polymerase chain reaction (RT-PCR) and western blotting, respectively. TSA stock solution (1 M) was prepared in DMSO and diluted with fresh complete medium immediately prior to use. The control cells were treated with DMSO (final concentration <0.1%).

Analysis of cell viability

Cell viability was determined by MTT assay. AtT-20 cells (5×104 cells/ml) were seeded in 96-well plates and incubated overnight. After TSA (2.5, 5, 10, 20 µM) treatment for 4, 8, 12, 16 or 24 h, cells were incubated at 37°C for 4 h with MTT solution (1 mg/ml), and then added 100 µl DMSO to dissolve formazan crystals. The absorbance was detected on a microplate reader (570 nm; Tecan Group Ltd., Männedorf, Austria). Cell viability was expressed as a percentage of the control group.

LDH leakage assay

AtT-20 cells (5×104 cells/ml) were seeded in 6-well plates and incubated overnight. Following TSA treatment (5, 10, 20 µM) for 4, 8, 12, 16 or 24 h, the culture medium was used to measure the amounts of lactate dehydrogenase (LDH) released using an LDH assay kit (Nanjing Jiancheng Bioengineering Institute, Nanjing, China), according to the manufacturer's protocol.

Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)

TUNEL kits (EMD Millipore, Billerica, MA, USA) were used to detect DNA fragmentation of apoptotic AtT-20 cells. AtT-20 cells (1×105 cells/ml) were seeded in 6-well plates and treated with increasing concentrations of TSA (5, 10, and 20 µM) for 12 h. Cells were incubated at 37°C for 1 h with terminal deoxynucleotidyl transferase enzyme, and then incubated for 30 min with the anti-digoxigenin conjugate. The cell nuclei were counterstained with DAPI. The fluorescence images were captured by a fluorescence microscope (Leica Microsystems GmbH, Wetzlar, Germany).

Quantification of the apoptosis rate

The apoptosis rate was detected by Annexin V/propidium iodide (PI) assay kits (Invitrogen; Thermo Fisher Scientific, Inc.). AtT-20 cells (1×105 cells/ml) were cultured in 6-well plates and treated with increasing concentrations of TSA (5, 10 and 20 µM) for 12 h. Cells were incubated for 15 min with Annexin V/PI (1 µg/ml) solution, and then analyzed using a FACSCalibur flow cytometer. Data were analyzed using CellQuest Pro software v1.0 (BD Biosciences, San Jose, CA, USA).

Detection of mitochondrial membrane potential

The mitochondrial membrane potential was detected using JC-1. AtT-20 cells (1×105 cells/ml) were cultured in 6-well plates and treated with increasing concentrations of TSA (5, 10 and 20 µM) for 12 h. Cells were then incubated at 37°C for 30 min with JC-1 (2 µM) and analyzed using a FACSCalibur flow cytometer.

Detection of caspase-3 activity

The caspase-3 activity was determined using a fluorescein-based active caspase-3 staining kit (BioVision, Inc., Milpitas, CA, USA). AtT-20 cells (1×105 cells/ml) were cultured in 6-well plates and treated with increasing concentrations of TSA (5, 10 and 20 µM) for 12 h. Cells were incubated for 10 min in chilled lysis buffer and then incubated at 37°C for additional 2 h in reaction buffer (containing 10 mM dithiothreitol and DEVD-7-amino-4-trifluoromethylcoumarin substrate). The fluorescence was detected using a microplate reader (excitation, 400 nm; emission, 505 nm). The caspase-3 activity was expressed as the percentage of the control.

Dual luciferase reporter assay

TCF-LEF reporter activity was determined using a dual luciferase reporter assay. A TCF-LEF reporter, obtained from SABiosciences (Qiagen, Inc., Valencia, CA, USA) is a mixture of inducible TCF-LEF-responsive firefly luciferase construct and constitutively expressed Renilla luciferase construct (40:1). AtT-20 cells (1×105 cells/well) were seeded in 6-well plates. When 60% confluence was observed, the cells were transiently transfected with TCF-LEF reporter using Lipofectamine 2000 (Thermo Fisher Scientific, Inc.). At 24 h after transfection, cells were treated with increasing concentrations of TSA (5, 10 and 20 µM) for 12 h. TCF-LEF reporter activity was measured using the dual luciferase reporter assay system (Promega Corporation, Madison, WI, USA). Luciferase activity was detected busing a GloMaxTM 96 microplate luminometer (Promega Corporation) The firefly luciferase values were normalized to the Renilla luciferase values. TCF-LEF activity was expressed as a percentage of the control.

Co-immunoprecipitation (co-IP)

The interaction between β-catenin and TCF-4 was detected using a Pierce co-immunoprecipitation kit (Thermo Fisher Scientific, Inc.). Briefly, AtT-20 cells (1×105 cells/well) were treated with increasing concentrations of TSA (5, 10 and 20 µM) for 12 h. The nuclear protein was obtained using cell nuclear protein extraction kits (Thermo Fisher Scientific, Inc.) and pre-cleared using the control agarose resin, and then incubated at 4°C with antibody against TCF-4 (1:200; ab185736, Abcam, Cambridge, MA, USA) immobilized to AminoLink Plus (Thermo Fisher Scientific, Inc.) coupling resin in reaction buffer. Immunoprecipitates were washed with lysis buffer and eluted with elution buffer. The level of β-catenin was analyzed by western blotting.

Western blot

The expression level of protein was analyzed by western blot. The total cytosol and nuclear protein extract were prepared using cell cytosol and nuclear protein extraction kits (Thermo Fisher Scientific, Inc.), respectively. The total protein concentration was determined using a bicinchonic acid assay. Proteins (20 µg) were resolved by 10% SDS-PAGE and transferred on PVDF membranes. The membranes were blocked with 2% BSA (Sigma-Aldrich; Merck KGaA) in TBS-Tween-20 (0.1%) at 4°C for 1 h. The membranes were incubated overnight at 4°C with the following primary antibodies: β-catenin (C-18; sc-1496; 1:200) p-β-catenin (Ser 33; sc-101650; 1:200), TCF-4 (F-7; sc-271288; 1:200), β-actin (C-2; sc-8432; 1:1,000) and lamin B (C-20; sc-6216; 1:200) from Santa Cruz Biotechnology, Inc., and cyclin D1 (ab134175; 1:1,000), MGMT (ab39253; 1:1,000) from Abcam (Cambridge, MA, USA). The membranes were incubated at 4°C for 1 h with respective horseradish peroxidase-conjugated goat anti-mouse (ab6789, Abcam, Cambridge, MA, USA) or goat anti-rabbit second antibodies (ab6721, Abcam, Cambridge, MA, USA). The immunoblots were visualized using enhanced chemiluminescence western blot detection kits (GE Healthcare Life Sciences, Chalfont, UK) and then visualized using a molecular imager with Image Lab 3.0 (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Equal loading of proteins was determined by β-actin or lamin B. The expression levels of the proteins were quantified using a densitometer (Molecular Devices, LLC, Sunnyvale, CA, USA).

Statistical analysis

The data represent the results from three independent experiments. The results are presented as the mean ± standard error of the mean. Student's two-tailed t-test and one-way ANOVA followed by Bonferroni's multiple comparison test were used for comparison between two groups and multiple groups, respectively. P<0.05 was considered statistically significant.

Results

TSA induces apoptosis in AtT-20 cells

The potential antitumor effect of TSA against AtT-20 cells was investigated. Treatment of AtT-20 cells with increasing concentrations of TSA for increasing periods of time reduced the cell viability (P<0.01, Fig. 1A) and increase LDH leakage (P<0.01; Fig. 1B) in concentration- and time-dependent manners.

Figure 1.

TSA induced apoptosis in AtT-20 cells. (A) TSA reduced the cell viability in a dose-dependent manner. (B) TSA increased the LDH leakage in a dose-dependent manner. (C) TSA increased the apoptotic cells rate in a dose-dependent manner. (D) TSA induced the mitochondrial membrane potential disruption in a dose-dependent manner. (E) Quantification of the apoptotic cells rate. (F) Quantification of JC-1 red/green fluorescence. *P<0.05, **P<0.01 vs. control. TSA, Tanshinone IIA; LDH, lactate dehydrogenase.

Phophatidylserine externalization, depolarization of mitochondrial membrane, caspase-3 activation and DNA fragmentation are the main features of apoptotic cells (10), and were detected by annexin V/PI staining and JC-1 staining (Fig. 1C-F), and caspase-3 activity assay (Fig. 2A) and TUNEL staining (Fig. 2B and C), respectively. TSA treatment significantly increased the percentage of apoptotic cells (P<0.01; Fig. 1C and E) and decreased mitochondrial membrane potential (P<0.01; Fig. 1D and F) compared with the control. Compared with the control group, caspase-3 activity (P<0.01; Fig. 2A) and TUNEL-positive cell rate (P<0.01; Fig. 2B and C) were increased by TSA in a dose-dependent manner.

Figure 2.

TSA induces caspase-3 activation and DNA fragmentation in AtT-20 cells. (A) TSA increased caspase-3 activity in a dose-dependent manner. (B) Quantification of TUNEL-positive cells rate. (C) TSA induced DNA fragmentation in AtT-20 cells in a dose-dependent manner. **P<0.01 vs. control. TSA, Tanshinone IIA; TUNEL, terminal deoxynucleotidyl transferase dUTP nick-end labeling.

TSA inhibited Wnt/β-catenin/MGMT pathway in AtT-20 cells

Dysregulation of the Wnt/β-catenin/MGMT pathway has a pivotal role in the pathogenesis of pituitary adenoma. A strategy to suppress the expression of MGMT by inhibition of Wnt/β-catenin signaling may be useful as a novel treatment for pituitary adenoma. Thus, whether TSA affects the Wnt/β-catenin/MGMT pathway was investigated. TSA treatment increased β-catenin phosphorylation and inhibited nuclear translocation of β-catenin in a dose-dependent manner (P<0.01; Fig. 3A and B). The levels of cyclin D1 and MGMT were detected to determine whether the inactivation of β-catenin mediated by TSA decreases the transcription of target genes. The protein levels of cyclin D1 and MGMT were significantly decreased by TSA treatment compared with the control (P<0.01; Fig. 3A). Importantly, co-IP results indicated that the interaction between β-catenin and TCF-4 was significantly reduced by TSA treatment in a dose-dependent manner (Fig. 3B, P<0.01). In accordance with these results, TSA treatment of AtT-20 cells transfected with a TCF-LEF reporter resulted in a dose-dependent reduction in TCF-LEF reporter activity (P<0.01; Fig. 3C).

Figure 3.

TSA inhibits Wnt/β-catenin/MGMT pathway. (A) The protein expression of p-β-catenin, cytosol β-catenin, cyclin D1 and MGMT determined by western blot. (B) The levels of β-catenin/TCF-4 complex detected by co-IP. (C) TCF-LEF reporter luciferase activity measured using the dual luciferase reporter assay system. **P<0.01 vs. control. TSA, Tanshinone IIA; MGMT, O6-methylguanine-DNA methyltransferase; TCF-4, T-cell factor; LEF, lymphoid-enhancing factor; IP, co-immunoprecipitation; IB, immunoblot.

TSA induces apoptosis via inhibition of Wnt/β-catenin/MGMT pathway in AtT-20 cells

To investigate whether Wnt/β-catenin/MGMT pathway was involved in TSA-mediated apoptosis, β-catenin knock down AtT-20 cells were infected with MGMT lentiviral activation particles. The inhibition of β-catenin nuclear translocation (Fig. 4A), decrease in TCF-LEF reporter activity (Fig. 4B, P<0.01), reduction in MGMT expression (Fig. 4A), phophatidylserine externalization (Fig. 4C), caspase-3 activation (Fig. 4D), DNA fragmentation (Fig. 4E), LDH leakage (Fig. 4F) and decrease in cell viability (Fig. 4G) induced by TSA were all significantly augmented in β-catenin knock down AtT-20 cells (P<0.01). However, overexpression of MGMT in β-catenin knock down AtT-20 cells reversed TSA-mediated phophatidylserine externalization (P<0.01; Fig. 4C), caspase-3 activation (P<0.01; Fig. 4D), DNA fragmentation (P<0.01; Fig. 4E), LDH leakage (P<0.01; Fig. 4F) and decrease in cell viability (P<0.01; Fig. 4G), suggesting that Wnt/β-catenin/MGMT inactivation is responsible for TSA-mediated antitumor effects.

Figure 4.

MGMT overexpression abolishes TSA-mediated apoptosis in β-catenin knock down AtT-20 cells. (A) The protein expression of nuclear β-catenin, total β-catenin and MGMT determined by western blot. (B) TCF-LEF reporter luciferase activity in β-catenin knock down AtT-20 cells. MGMT overexpression abolished TSA-mediated increase in (C) the apoptotic cells rate, (D) caspase-3 activation, (E) DNA fragmentation, (F) LDH leakage and (G) the decrease in cell viability. ##P<0.01 vs. control; **P<0.01 vs. TSA treatment alone. TSA, Tanshinone IIA; p-β-catenin; phosphorylated β-catenin; MGMT, O6-methylguanine-DNA methyltransferase; TCF-4, T-cell factor; LEF, lymphoid-enhancing factor; TUNEL, terminal deoxynucleotidyl transferase dUTP nick-end labeling; LDH, lactate dehydrogenase.

Discussion

The current study confirmed that TSA induces apoptosis in AtT-20 cells. Apoptosis is generally characterized by phophatidylserine externalization, depolarization of mitochondrial membrane, caspase-3 activation and DNA fragmentation (11,12). Previous studies have indicated that TSA has anti-tumor effects on glioma cells (13), osteosarcoma cells (14) and gastric cancer cells (15). In the present study, TSA treatment resulted in cell viability reduction, phophatidylserine externalization, mitochondrial membrane potential disruption, caspases-3 activation and DNA fragmentation in AtT-20 cells. These results suggest that TSA induced apoptosis in AtT-20 cells, suggesting that TSA may be a candidate drug for treatment of pituitary adenoma.

The principal finding of this study is that TSA induces apoptosis in AtT-20 cells via downregulating Wnt/β-catenin/MGMT signaling. The canonical Wnt/β-catenin cascade, the non-canonical planar cell polarity pathway and the Wnt/Ca2+ pathway are involved in Wnt receptor activation (16). The Wnt/β-catenin pathway can regulate MGMT gene expression in cancer, and inhibition of Wnt signalling can prevent chemoresistance (17). Dysregulation of the Wnt/β-catenin/MGMT pathway has a pivotal role in the pathogenesis of pituitary adenoma (18,19). In the present study, TSA increased the phosphorylation of β-catenin, and inhibited its nuclear translocation in AtT-20 cells. Notably, co-IP results revealed that β-catenin/TCF-4 binding was significantly reduced by TSA treatment, meanwhile, TSA treatment of AtT-20 cells transiently transfected with TCF-LEF reporter resulted in a marked decrease in TCF-LEF activity. These results indicated that when activated β-catenin translocated to the nucleus, combined with TCF-4 and interacted with TCF-LEF, resulting in transcription of target genes, including cyclin D1 and MGMT. The results of the present study are in agreement with a previous study, which observed that TSA inhibited the transdifferentiation of renal tubular epithelial cells induced by high glucose via downregulation of the Wnt/beta-catenin signaling pathway activity (20).

Notably, TSA-mediated suppression of Wnt/β-catenin/MGMT pathway and apoptosis were exacerbated in β-catenin KO cells, however, TSA-mediated apoptosis was abolished by MGMT overexpression in β-catenin knock down cells. To the best of our knowledge, this study is the first to demonstrate that Wnt/β-catenin/MGMT inactivation is mediates for TSA-induced apoptosis in AtT-20 cells.

In conclusion, TSA induced apoptosis by inactivating the Wnt/β-catenin/MGMT pathways in AtT-20 cells, which provides a novel insight into the mechanism underlying the antitumor effects of Salvia miltiorrhiza extract. The results of the present study must be further investigated, particularly through the use of an in vivo model.

Acknowledgements

This project was supported by the Basic research projects of Shenzhen Science and Technology Program (grant nos. JCYJ20140414170821309, JCYJ20150306114616, JCYJ20150330102720152 and JCYJ2920831101643895), the Natural Science Foundation of Guangdong (grant no. 2015A030313777), the Research Fund from Shenzhen Key Laboratory of Neurosurgery (grant no. ZDSYS20140509173142601).

References

1 

Gurcan O, Gurcay AG, Kazanci A, Yildirim AE, Turkoglu OF, Komurcu HF and Beskonakli E: Trigeminal neuralgia as an unusual isolated symptom of pituitary Adenoma: Case report and review of the literature. Turk Neurosurg. 26:180–183. 2016.PubMed/NCBI

2 

Bengtsson D, Schrøder HD, Andersen M, Maiter D, Berinder K, Rasmussen U Feldt, Rasmussen ÅK, Johannsson G, Hoybye C, Van Der Lely AJ, et al: Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. J Clin Endocrinol Metab. 100:1689–1698. 2015. View Article : Google Scholar : PubMed/NCBI

3 

McCormack A, Kaplan W, Gill AJ, Little N, Cook R, Robinson B and Clifton-Bligh R: MGMT expression and pituitary tumours: Relationship to tumour biology. Pituitary. 16:208–219. 2013. View Article : Google Scholar : PubMed/NCBI

4 

Chen YP, Hou XY, Yang CS, Jiang XX, Yang M, Xu XF, Feng SX, Liu YQ and Jiang G: DNA methylation and histone acetylation regulate the expression of MGMT and chemosensitivity to temozolomide in malignant melanoma cell lines. Tumour Biol. 37:11209–11218. 2016. View Article : Google Scholar : PubMed/NCBI

5 

Wickström M, Dyberg C, Milosevic J, Einvik C, Calero R, Sveinbjörnsson B, Sandén E, Darabi A, Siesjö P, Kool M, et al: Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents. chemoresistance. 6:89042015.

6 

Khattak MN, Buchfelder M, Kleindienst A, Schöfl C and Kremenevskaja N: CRH and SRIF have opposite effects on the Wnt/β-catenin signalling pathway through PKA/GSK-3β in corticotroph pituitary cells. Cancer Invest. 28:797–805. 2010. View Article : Google Scholar : PubMed/NCBI

7 

Das A, Miller R, Lee P, Holden CA, Lindhorst SM, Jaboin J, Vandergrift WA III, Banik NL, Giglio P, Varma AK, et al: A novel component from citrus, ginger, and mushroom family exhibits antitumor activity on human meningioma cells through suppressing the Wnt/β-catenin signaling pathway. Tumour Biol. 36:7027–7034. 2015. View Article : Google Scholar : PubMed/NCBI

8 

Xing Y, Tu J, Zheng L, Guo L and Xi T: Anti-angiogenic effect of tanshinone IIA involves inhibition of the VEGF/VEGFR2 pathway in vascular endothelial cells. Oncol Rep. 33:163–170. 2015. View Article : Google Scholar : PubMed/NCBI

9 

Bai Y, Zhang L, Fang X and Yang Y: Tanshinone IIA enhances chemosensitivity of colon cancer cells by suppressing nuclear factor-κB. Exp Ther Med. 11:1085–1089. 2016. View Article : Google Scholar : PubMed/NCBI

10 

Prokhorova EA, Zamaraev AV, Kopeina GS, Zhivotovsky B and Lavrik IN: Role of the nucleus in apoptosis: Signaling and execution. Cell Mol Life Sci. 72:4593–4612. 2015. View Article : Google Scholar : PubMed/NCBI

11 

Jellinger KA: Challenges in neuronal apoptosis. Curr Alzheimer Res. 3:377–391. 2006. View Article : Google Scholar : PubMed/NCBI

12 

Hunter AL, Choy JC and Granville DJ: Detection of apoptosis in cardiovascular diseases. Methods Mol Med. 112:277–289. 2005.PubMed/NCBI

13 

Ding L, Ding L, Wang S, Wang S, Wang W, Wang W, Lv P, Lv P, Zhao D, Zhao D, et al: Tanshinone IIA affects autophagy and apoptosis of glioma cells by inhibiting phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling pathway. Pharmacology. 99:188–195. 2017. View Article : Google Scholar : PubMed/NCBI

14 

Huang ST, Huang CC, Huang WL, Lin TK, Liao PL, Wang PW, Liou CW and Chuang JH: Tanshinone IIA induces intrinsic apoptosis in osteosarcoma cells both in vivo and in vitro associated with mitochondrial dysfunction. Sci Rep. 7:403822017. View Article : Google Scholar : PubMed/NCBI

15 

Yu J, Wang X, Li Y and Tang B: Tanshinone IIA suppresses gastric cancer cell proliferation and migration by downregulation of FOXM1. Oncol Rep. 37:1394–1400. 2017. View Article : Google Scholar : PubMed/NCBI

16 

Clevers H: Wnt/beta-catenin signaling in development and disease. Cell. 127:469–480. 2006. View Article : Google Scholar : PubMed/NCBI

17 

Wickström M, Dyberg C, Milosevic J, Einvik C, Calero R, Sveinbjörnsson B, Sandén E, Darabi A, Siesjö P, Kool M, et al: Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance. Nat Commun. 6:89042015. View Article : Google Scholar : PubMed/NCBI

18 

Formosa R, Gruppetta M, Falzon S, Santillo G, DeGaetano J, Xuereb-Anastasi A and Vassallo J: Expression and clinical significance of Wnt players and survivin in pituitary tumours. Endocr Pathol. 23:123–131. 2012. View Article : Google Scholar : PubMed/NCBI

19 

Maïza JC and Caron P: Pituitary carcinomas and aggressive adenomas: An overview and new therapeutic options. Ann Endocrinol (Paris). 70 Suppl 1:S12–S19. 2009.(In French). View Article : Google Scholar : PubMed/NCBI

20 

Huang BY, Cao LY and Fu XG: Effects of tanshinone IIA on Wnt/beta-catenin signaling pathway of high glucose induced renal tubular epithelial cell transdifferentiation. Zhongguo Zhong Xi Yi Jie He Za Zhi. 32:965–969. 2012.(In Chinese). PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Li ZY, Huang GD, Chen L, Zhang C, Chen BD, Li QZ, Wang X, Zhang XJ and Li WP: Tanshinone IIA induces apoptosis via inhibition of Wnt/β‑catenin/MGMT signaling in AtT‑20 cells. Mol Med Rep 16: 5908-5914, 2017.
APA
Li, Z., Huang, G., Chen, L., Zhang, C., Chen, B., Li, Q. ... Li, W. (2017). Tanshinone IIA induces apoptosis via inhibition of Wnt/β‑catenin/MGMT signaling in AtT‑20 cells. Molecular Medicine Reports, 16, 5908-5914. https://doi.org/10.3892/mmr.2017.7325
MLA
Li, Z., Huang, G., Chen, L., Zhang, C., Chen, B., Li, Q., Wang, X., Zhang, X., Li, W."Tanshinone IIA induces apoptosis via inhibition of Wnt/β‑catenin/MGMT signaling in AtT‑20 cells". Molecular Medicine Reports 16.5 (2017): 5908-5914.
Chicago
Li, Z., Huang, G., Chen, L., Zhang, C., Chen, B., Li, Q., Wang, X., Zhang, X., Li, W."Tanshinone IIA induces apoptosis via inhibition of Wnt/β‑catenin/MGMT signaling in AtT‑20 cells". Molecular Medicine Reports 16, no. 5 (2017): 5908-5914. https://doi.org/10.3892/mmr.2017.7325
Copy and paste a formatted citation
x
Spandidos Publications style
Li ZY, Huang GD, Chen L, Zhang C, Chen BD, Li QZ, Wang X, Zhang XJ and Li WP: Tanshinone IIA induces apoptosis via inhibition of Wnt/β‑catenin/MGMT signaling in AtT‑20 cells. Mol Med Rep 16: 5908-5914, 2017.
APA
Li, Z., Huang, G., Chen, L., Zhang, C., Chen, B., Li, Q. ... Li, W. (2017). Tanshinone IIA induces apoptosis via inhibition of Wnt/β‑catenin/MGMT signaling in AtT‑20 cells. Molecular Medicine Reports, 16, 5908-5914. https://doi.org/10.3892/mmr.2017.7325
MLA
Li, Z., Huang, G., Chen, L., Zhang, C., Chen, B., Li, Q., Wang, X., Zhang, X., Li, W."Tanshinone IIA induces apoptosis via inhibition of Wnt/β‑catenin/MGMT signaling in AtT‑20 cells". Molecular Medicine Reports 16.5 (2017): 5908-5914.
Chicago
Li, Z., Huang, G., Chen, L., Zhang, C., Chen, B., Li, Q., Wang, X., Zhang, X., Li, W."Tanshinone IIA induces apoptosis via inhibition of Wnt/β‑catenin/MGMT signaling in AtT‑20 cells". Molecular Medicine Reports 16, no. 5 (2017): 5908-5914. https://doi.org/10.3892/mmr.2017.7325
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team